H.C. Wainwright reiterates Erasca stock rating on phase 1 data By Investing.com

Erasca reported preliminary Phase 1 data for ERAS-0015 showing a 62% unconfirmed ORR in second-line or later KRAS G12X NSCLC, 75% in post-immunotherapy/platinum NSCLC, and 40%-42% in second-line pancreatic ductal adenocarcinoma, all ahead of expectations. H.C. Wainwright reiterated a Buy rating with a $20 price target, while Stifel raised its target to $30 and BofA lifted its target to $9 despite an Underperform rating. The stock has surged more than 1,260% over the past year, reflecting strong investor enthusiasm around the early clinical readout.

Analysis

The market is now pricing ERAS less like a binary early-stage biotech and more like a platform validation story, which is why the stock can stay elevated despite limited follow-up. The key second-order effect is that strong first-pass efficacy in hard-to-treat RAS tumors shifts investor attention from probability of technical success to how quickly the company can translate a single asset into multiple shots on goal. That usually supports a higher multiple for 3-6 months, but it also increases sensitivity to any sign that durability, dose optimization, or safety narrows the commercial window.

The biggest winner may be not just ERAS equity holders but the financing ecosystem around pan-RAS and KRAS programs. A credible read-through here raises the bar for adjacent names pursuing differentiated mechanisms, while making “me-too” RAS approaches look like funding casualties if they cannot show a cleaner tolerability profile or broader mutation coverage. In practice, that can create a consolidation bid for the best-positioned follow-on assets and a re-rating dispersion across the basket.

The contrarian risk is that the move has already front-loaded much of the good news: with the stock having rerated dramatically, the next catalyst must prove not just activity but durability and dosing economics. If the upcoming full data show response attrition, dose-limiting toxicity, or weaker PDAC consistency, the multiple can compress quickly because the market has shifted from valuing option value to paying for execution. The right lens is not whether the program is active, but whether it can remain competitively active when the novelty premium fades over the next 1-2 quarters.

Key Decisions for Investors

• Stay long ERAS tactically only into the full-data window in mid-May 2026; use a trailing stop or collar structure because upside is now more dependent on confirmation than on discovery.
• For traders, consider an ERAS call spread rather than outright equity exposure into the next readout cycle: defined downside, still captures upside if durability and safety hold, and avoids paying full vol on a stock that has already re-rated sharply.
• Pair trade: long ERAS vs short a basket of less-differentiated early RAS names over the next 3-6 months, on the view that capital will continue to concentrate in the clearest efficacy winner while weaker programs de-rate.
• If already long, trim into strength and re-add only on post-data consolidation; the stock’s current setup is more vulnerable to a 20-30% air pocket on any minor disappointment than to another clean upside surprise.
• For event-driven funds, set a hedge around the readout using short-dated puts or a put spread into late Q1/early Q2 2026, when sentiment will likely peak and implied expectations become most fragile.